Tumor Membrane Vesicle Vaccine Augments the Efficacy of Anti-PD1 Antibody in Immune Checkpoint Inhibitor-Resistant Squamous Cell Carcinoma Models of Head and Neck Cancer

Immune checkpoint inhibitor (ICI) immunotherapy improved the survival of head and neck squamous cell carcinoma (HNSCC) patients. However, more than 80% of the patients are still resistant to this therapy. To test whether the efficacy of ICI therapy can be improved by vaccine-induced immunity, we inv...

Descripción completa

Detalles Bibliográficos
Autores principales: Bommireddy, Ramireddy, Munoz, Luis E., Kumari, Anita, Huang, Lei, Fan, Yijian, Monterroza, Lenore, Pack, Christopher D., Ramachandiran, Sampath, Reddy, Shaker J.C., Kim, Janet, Chen, Zhuo G., Saba, Nabil F., Shin, Dong M., Selvaraj, Periasamy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348725/
https://www.ncbi.nlm.nih.gov/pubmed/32295135
http://dx.doi.org/10.3390/vaccines8020182

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348725/
https://www.ncbi.nlm.nih.gov/pubmed/32295135
http://dx.doi.org/10.3390/vaccines8020182

Ejemplares similares